Table 4 Multivariate analysis of prognostic factors in patients with stage IE/IIE primary breast lymphoma
| Â | PFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Pathological types | ||||
 DLBCL | - |  |  |  |
 Non-DLBCL | 3.745 (1.718–8.196) | 0.001 |  |  |
Rituximab | ||||
 Yes | - |  |  |  |
 No | 5.76 (1.979–16.784) | 0.001 |  |  |
Nodal sites involved | ||||
 Yes |  |  | - | 0.005 |
 No |  |  | 0.24 (0.091–0.661) | |
Radiotherapy | ||||
 Yes |  |  | - | 0.003 |
 No |  |  | 3.975 (1.607–9.832) | |